Abstract:Abstract Background: Macrophages are one of the major infiltrating immune cells in the tumor microenvironment and have been proposed as a primary driver of epithelial to mesenchymal transition (EMT) through interactions with tumour cells. These interactions play a key role in tumor progression, metastasis and fibrosis, processes which are common to all types of cancer. Understandably therefore, targeting macrophages is an attractive approach for treating wide range of tumors including those resistant to checkpoint inhibitors. Evaluation of cancer therapeutics is hampered by a lack of suitable in vitro models which closely recapitulate the complexity of tumor microenvironment. We addressed this challenge by developing a model system with potential to faithfully represent the key molecular interactions occurring between tumor associated macrophages and cancer cells, driving the latter to become invasive and metastatic. In order to demonstrate suitability of the assay, galunisertib, a TGFbRI/ALK5 inhibitor was used to block one of pathways that has been evaluated clinically in cancer patients. Methods: Human macrophages were differentiated using key growth factors prior to polarisation with various cytokines to generate different putative macrophage phenotypes as evidenced by differences in cytokine secretion, gene transcription and protein expression. Epithelial cells were stimulated with macrophage conditioned medium in a scratch wound assay (Incucyte) and analysed by immunocytochemistry. Results: Macrophages derived supernatants were shown to drive EMT, both in migratory capacity and EMT associated protein expression. Our results demonstrate that whilst galunisertib could potently inhibit TGF-b driven EMT it was only partly capable of reversing the effects associated with addition of macrophage conditioned media. Conclusions: The data show that macrophages can directly drive the EMT process in vitro via multiple mechanisms. One such mechanism is through the secretion of TGF-b. Indeed, blockade of TGF-b signalling appears to be a tangible approach in cancer immunotherapy, but to date this approach has delivered mixed results for clinical efficacy as a monotherapy. By way of example, development of galunisertib has recently been halted. As shown herein, macrophages effects on cancer migration and metastasis span beyond TGF-b only effects. We offer a potential explanation for why single therapies such as galunisertib alone are ineffective in cancer treatment. The described model provides a powerful tool to researchers to better understand and replicate in vitro the complex interactions occurring in the tumor microenvironment. Thus, enabling the identification of molecular targets and combination therapies with potential to block cancer cell migration and metastasis and to evaluate candidate drug efficacy. Citation Format: Darryl Turner, Ross Dobie, Justyna Rzepecka, Hayley Gooding, Matilda Bingham. Deciphering macrophage targeting cancer immunotherapies using a novel in vitro assay modelling the tumor microenvironment [abstract]. In: Proceedings of the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; 2023 Oct 11-15; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2023;22(12 Suppl):Abstract nr A122.

Mathematical modeling of tumor-associated macrophage interactions with the cancer microenvironment

Modeling of tumor response to macrophage and T lymphocyte interactions in the liver metastatic microenvironment

Agent-based modeling of tumor-immune interactions reveals determinants of final tumor states

Multi-scale modeling of macrophage—T cell interactions within the tumor microenvironment

Computational Modeling of the Crosstalk Between Macrophage Polarization and Tumor Cell Plasticity in the Tumor Microenvironment

Data-driven mathematical modeling and quantitative analysis of cell dynamics in the tumor microenvironment

Mathematical investigation into the role of macrophage heterogeneity on the temporal and spatio-temporal dynamics of non-small cell lung cancers

Tumor-on-a-chip Platform to Interrogate the Role of Macrophages in Tumor Progression

Abstract A122: Deciphering macrophage targeting cancer immunotherapies using a novel in vitro assay modelling the tumor microenvironment

Immune cells interactions in the tumor microenvironment

Investigation into the role of macrophages heterogeneity on solid tumour aggregations

Modeling tumor-immune interactions using hybrid spheroids and microfluidic platforms for studying tumor-associated macrophage polarization in melanoma

Targeting the Tumor Microenvironment: A Close Up of Tumor-Associated Macrophages and Neutrophils

Mathematical modeling and bifurcation analysis of pro- and anti-tumor macrophages

Mathematical Modeling Predicts Synergistic Antitumor Effects of Combining a Macrophage-Based, Hypoxia-Targeted Gene Therapy with Chemotherapy

Mathematical Modeling of the Metastatic Colorectal Cancer Microenvironment Defines the Importance of Cytotoxic Lymphocyte Infiltration and Presence of PD-L1 on Antigen Presenting Cells

Modelling the tumor immune microenvironment for precision immunotherapy

Mathematical model of tumor immune microenvironment with application to the combined therapy targeting the PD-1/PD-L1 pathway and IL-10 cytokine antibody

Mechanistic studies of tumor-associated macrophage immunotherapy

Abstract A037: Mathematical modeling of the tumor-immune microenvironment in murine colon adenocarcinoma

Quantitative Modeling to Understand Cell Signaling in the Tumor Microenvironment